MedPath

A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.

Not Applicable
Conditions
Advanced or recurrent lung cancer
Registration Number
JPRN-UMIN000053550
Lead Sponsor
iigata University Medical and Dental Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
165
Inclusion Criteria

Not provided

Exclusion Criteria

(1) FDG uptake on lung region was difficult to evaluate owing to massive consolidation or pleural effusion (2) Patients with bilateral multiple primary lung cancers.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Interstitial lung disease after administration of immune checkpoint inhibitors
Secondary Outcome Measures
NameTimeMethod
Prognosis after administration of immune checkpoint inhibitors
© Copyright 2025. All Rights Reserved by MedPath